All In Biotech

Drug Trial Radar · NCT06799247

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

128

Actual

Start

May 6, 2025

Primary completion

Dec 30, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Cartesian TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.

Conditions

  • Myasthaenia Gravis

Interventions

  • Decartes-08Biological

    Autologous mRNA CAR T-cell therapy

  • Placebo DrugOther

    infusion without Decartes-08

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myasthenia Gravis Activities of Daily Living (MG-ADL)Time frame: assessment at 4 months of study

Locations

34 sites in 8 countries. Site status is shown where the registry gives one.

  • A40

    Tucson, Arizona

  • A13

    Carlsbad, California

  • A46

    Los Angeles, California

  • A14

    Orange, California

  • A21

    Aurora, Colorado

  • A50

    Washington D.C., District of Columbia

  • A48

    Maitland, Florida

  • A10

    Tampa, Florida

  • A53

    O'Fallon, Illinois

  • A20

    Fairway, Kansas

  • A16

    Lexington, Kentucky

  • A38

    Boston, Massachusetts

  • A12

    Amherst, New York

  • A52

    New York, New York

  • A47

    New York, New York

  • A22

    Chapel Hill, North Carolina

  • A39

    Charlotte, North Carolina

  • A15

    Portland, Oregon

  • A11

    Philadelphia, Pennsylvania

  • A49

    Pittsburgh, Pennsylvania

  • A43

    Houston, Texas

  • A41

    Seattle, Washington

  • A54

    Milwaukee, Wisconsin

  • A18

    Toronto, Canada

  • A23

    Rome, Italy

  • A30

    Krakow, Poland

  • A24

    Belgrade, Serbia

  • A25

    Barcelona, Spain

  • A26

    Barcelona, Spain

  • A31

    Madrid, Spain

  • A32

    Ankara, Turkey (Türkiye)

  • A17

    Istanbul, Turkey (Türkiye)

  • A33

    Birmingham, United Kingdom

  • A51

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.